5 New Stock Picks of Billionaire Ray Dalio

2. BioNTech SE (NASDAQ:BNTX)

Number of Hedge Fund Holders: 26 

BioNTech SE (NASDAQ:BNTX) is a biotech firm based in Germany. Latest filings show that Bridgewater Associates owned over 12,000 shares of BioNTech SE (NASDAQ:BNTX) at the end of the second quarter of 2022 worth $1.8 million. 

On August 17, Cowen analyst Yaron Werber initiated coverage of BioNTech SE (NASDAQ:BNTX) stock with a Market Perform rating and a price target of $177, noting that the deep oncology pipeline of the firm was innovative but required validation. 

At the end of the second quarter of 2022, 26 hedge funds in the database of Insider Monkey held stakes worth $380 million in BioNTech SE (NASDAQ:BNTX), compared to 29 the preceding quarter worth $409 million.

In its Q3 2021 investor letter, Baron Funds, an asset management firm, highlighted a few stocks and BioNTech SE (NASDAQ:BNTX) was one of them. Here is what the fund said:

“BioNTech SE (NASDAQ:BNTX) is a leader in the emerging field of mRNA drugs, with additional programs in engineered cell therapies, antibodies, and immunomodulators. Shares performed well for the quarter. The COVID-19 vaccine rollout continues with the addition of a booster shot, and we believe the pandemic has been a strong proof point of the speed and efficacy of the mRNA platform. Beyond vaccines, we think BioNTech SE (NASDAQ:BNTX) has potential to disrupt the biopharmaceutical space with a pipeline spanning oncology, infectious diseases, and rare diseases.”